MétaCan
Menu
Back to cohort
Record W4404731599 · doi:10.1101/2024.11.25.24317569

Beyond HER2 expression in breast cancer: Investigating alternative splicing profiles as a mechanism of resistance to anti-HER2 therapies

2024· preprint· en· W4404731599 on OpenAlexaff
Gabriela D. A. Guardia, Carlos Henrique dos Anjos, Aline Rangel‐Pozzo, Filipe F. dos Santos, Alexander Birbrair, Paula Fontes Asprino, Anamaria A. Camargo, Pedro A. F. Galante

Bibliographic record

VenuemedRxiv · 2024
Typepreprint
Languageen
FieldMedicine
TopicCell Adhesion Molecules Research
Canadian institutionsUniversity of ManitobaCancerCare Manitoba
Fundersnot available
KeywordsTrastuzumabAlternative splicingGene isoformBreast cancerRNA splicingCancer researchBiologyReceptor tyrosine kinaseComputational biologyCancerBioinformaticsMedicineSignal transductionGeneGeneticsRNA

Abstract

fetched live from OpenAlex

Breast cancer is a heterogeneous disease that can be molecularly classified based on the expression of hormone receptors and the overexpression of the HER2 receptor (ERBB2). Targeted therapies for HER2-positive breast cancer, including trastuzumab, antibody drug conjugates (ADCs) and tyrosine kinase inhibitors, have significantly improved patient outcomes. However, both primary and acquired resistance to these treatments pose challenges that can limit their long-term efficacy. Addressing these obstacles is vital for enhancing therapeutic strategies and patient care. Alternative splicing, a post-transcriptional mechanism that enhances transcript diversity (isoforms) within a cell, can result in isoform-encoded proteins with varied functions, cellular localizations, or binding properties. In this study, we undertook a comprehensive characterization of the alternative splicing isoforms of HER2, assessed their expression levels in primary breast tumors and cell lines, and explored their role in resistance to anti-HER2 therapies. Our results have significantly expanded the catalog of known HER2 protein-coding isoforms from 13 to 90, revealing distinct patterns of protein domains, cellular localization, and protein structures, as well as mapping their antibody-binding sites. Additionally, by profiling expression in 561 primary breast cancer samples and analyzing mass spectrometry data for translation evidence, we discovered a complex landscape of splicing isoform expression in primary tumors, revealing novel isoforms that were previously unrecognized and are not evaluated in routine clinical practice. This extends beyond the traditional profile based solely on HER2 gene expression and translation. Finally, by assessing HER2 isoform expression in cell cultures that are either sensitive or resistant to trastuzumab and ADCs (T-DM1 or T-DXd), we found that drug-resistant tumor cells shifted their expression toward splicing isoforms that lack the antibody-binding domains. Our results substantially broaden the understanding of HER2 protein-coding isoforms, revealing distinct mechanisms of potential resistance to anti-HER2 therapies, particularly ADCs, by uncovering a new dimension of splicing isoform diversity. This expanded landscape of HER2 isoforms, marked by unique domain patterns and altered antibody-binding sites, emphasizes the crucial role of alternative splicing investigations in advancing precision-targeted cancer therapies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.002

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.333
Teacher spread0.307 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2024
Admission routes1
Has abstractyes

Explore more

Same venuemedRxivSame topicCell Adhesion Molecules ResearchFrench-language works237,207